Investigational drug · Phase 3
NBI-1065845
Also called: TAK-653, Osavampator
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
6
Any phase or sponsor naming "NBI-1065845"
First trial start
2025
Jan 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NBI-1065845", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "NBI-1065845" as an intervention, largest first.
- Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06966401 · 850 participants (planned) · Start Apr 16, 2025 · Primary completion May 2029
Drug: NBI-1065845 · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Bryant, Arkansas; Little Rock, Arkansas · 120 sites in all
- A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07196501 · 550 participants (planned) · Start Aug 18, 2025 · Primary completion Jul 2028
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Oceanside, California; Orange, California; San Jose, California · 61 sites in all
- Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06786624 · 200 participants (planned) · Start Jan 22, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Garden Grove, California; Orange, California · 30 sites in all
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06911112 · 200 participants (planned) · Start Mar 31, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Huntsville, Alabama; Bryant, Arkansas; Cerritos, California · 42 sites in all
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Pivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT06963021 · 200 participants (planned) · Start May 30, 2025 · Primary completion Jul 2027
Drug: Osavampator; Placebo · For: Major Depressive Disorder
Sites: Chino, California; Los Angeles, California; Stanford, California · 39 sites in all
- Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)Pivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT05203341 · 183 participants · Start Feb 21, 2022 · Primary completion Jan 10, 2024
Drug: Placebo; NBI-1065845 · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Huntsville, Alabama; Riverside, California · 41 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of a fluorinated benzoxathiazine AMPA receptor PAM that stabilizes the GluA2 dimer interface and displays antidepressant-like effects.
Wei L, Yu X, Zheng Y, et al. · Eur J Med Chem 2027
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Positive allosteric modulators of AMPA receptors: advances and emerging trends.
Colson T, Pirotte B, Francotte P · Expert Opin Ther Pat 2026
- All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants.
Freudenberg F, Reif-Leonhard C, Dawson GR, et al. · Pharmacol Res 2025
- TAK-653 Reverses Core Depressive Symptoms in Chronic Stress-Induced Monkey Model.
Li L, Zhang Z, Liu X, et al. · Biomedicines 2025
- Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
Lin S, Ionescu A, Maynard-Scott J, et al. · Clin Transl Sci 2024
Also in development for Major Depressive Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- CYM-53093Navacaprant, NMRA-335140Phase 34 trials
Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
- CYB003Phase 33 trials
Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Neurocrine Biosciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.